|Mr. David Darling||CEO, MD & Exec. Director||N/A||N/A||N/A|
|Ms. Kate Rankin||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Jimmy Suttie||Sr. VP of Global Operations||N/A||N/A||N/A|
|Dr. Parry Guilford Ph.D.||Chief Scientific Officer & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Jack Atchason||Sr. VP of Sales & Customer Service, Pacific Edge Diagnostics USA Limited||N/A||N/A||N/A|
Pacific Edge Limited, a cancer diagnostic company, develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a suite of non-invasive laboratory tests for the deduction and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; and Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers, which are in clinical and user trials. In addition, the company is developing products for gastric, melanoma, and endometrial cancers, which are in pre-clinical trials. Pacific Edge Limited was founded in 2001 and is headquartered in Dunedin, New Zealand.
Pacific Edge Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.